Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 19/20 | 0.70 |
| ▸ | CCNT1 | O60563 | 17/20 | 0.70 |
| ▸ | CCNK | O75909 | 1/20 | 0.62 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.62 |
| ▸ | CASP3 | P42574 | 2/20 | 0.59 |
| ▸ | CASP7 | P55210 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16041785 | 0.90 | CDK9 (0.70) | CDK9CCNT1CCNKCDK12CASP3 | |
| SCHEMBL16039904 | 0.89 | CDK9 (0.71) | CDK9CCNT1CCNKCDK12CASP3 | |
| SCHEMBL16041611 | 0.88 | CDK9 (0.85) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL16041083 | 0.88 | CDK9 (0.70) | CDK9CCNT1CCNKCDK12CASP3 | |
| SCHEMBL16039733 | 0.87 | CDK9 (0.71) | CDK9CCNT1CCNKCDK12CASP3 | |
| SCHEMBL27382602 | 0.86 | CDK9 (0.79) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL16042926 | 0.86 | CDK9 (0.66) | CDK9CCNT1CCNKCDK12CASP3 | |
| SCHEMBL16040950 | 0.85 | CDK9 (0.65) | CDK9CCNT1CCNKCDK12CASP3 | |
| SCHEMBL16050566 | 0.84 | CCNT1 (0.80) | CDK9CCNT1CASP3CASP7 | |
| SCHEMBL16042306 | 0.84 | CDK9 (0.68) | CDK9CCNT1CCNKCDK12CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796708-B2 | Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors | ABBVIE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-9073922-B2 | Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors | ABBVIE, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060257-A1 | PYRROLO [2,3-B] PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | CDK9 1/4885CCNT1 36/4885CCNK 20/4885 |
| US-20140275027-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | CDK9, CDK19, CDK3 | CDK9 1/4885CCNT1 36/4885CCNK 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.